TC
CRL icon

Truvestments Capital’s Charles River Laboratories CRL Stock Holding History

Truvestments Capital’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$36.7K Sell
162
-38
-19% -$6.77K 0.01% 592
2026
Q1 		$34.5K Sell
200
-86
-30% -$15.9K 0.01% 554
2025
Q4 		$57.1K Sell
286
-29
-9% -$5.26K 0.01% 424
2025
Q3 		$49.3K Sell
315
-174
-36% -$27.6K 0.01% 442
2025
Q2 		$74.2K Sell
489
-63
-11% -$8.4K 0.01% 330
2025
Q1 		$83.1K Sell
552
-2,010
-78% -$337K 0.02% 318
2024
Q4 		$473K Buy
2,562
+155
+6% +$29.9K 0.12% 136
2024
Q3 		$474K Buy
2,407
+350
+17% +$72.7K 0.13% 132
2024
Q2 		$425K Buy
2,057
+409
+25% +$92.7K 0.17% 133
2024
Q1 		$447K Buy
+1,648
New +$394K 0.17% 123
2023
Q1 		– Sell
-8
Closed -$1.74K – 726
2022
Q4 		$1.74K Hold
8
– – ﹤0.01% 752
2022
Q3 		$2K Hold
8
– – ﹤0.01% 546
2022
Q2 		$2K Buy
+8
New +$1.96K ﹤0.01% 554
2018
Q3 		$6K Buy
+45
New +$5.55K ﹤0.01% 715

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Truvestments Capital's CRL Position: Q2 2026 in Review

Truvestments Capital reduced its Charles River Laboratories (CRL) stake by 19% in Q2 2026, selling an estimated $6.77K and leaving 162 shares worth $36.7K. The position accounts for 0.01% of the portfolio, ranked #592.

Truvestments Capital first reported a position in CRL in Q3 2018 and has held it in 14 quarters since. The position peaked at $474K in Q3 2024. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Truvestments Capital held 162 shares of Charles River Laboratories worth $36.7K as of Q2 2026.
  • Truvestments Capital sold 38 Charles River Laboratories shares in Q2 2026, an estimated $6.77K.
  • Charles River Laboratories made up 0.01% of Truvestments Capital's portfolio in Q2 2026, its #592 holding.
  • Truvestments Capital first reported a position in Charles River Laboratories in Q3 2018 and has held it in 14 quarters since.
  • Truvestments Capital's Charles River Laboratories position peaked at $474K in Q3 2024.
  • 570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Truvestments Capital's 13F filing for Q2 2026, filed 12 Aug 2026.